Tharimmune, Inc. — Director's Dealing 2022

Apr 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Hillstream BioPharma Inc. (HILS)
CIK: 0001861657
Period of Report: 2022-04-18

Reporting Person: MILBY RANDY (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-04-18	Common Stock	X	7575	$0.314	Acquired	2701588	Direct
2022-04-18	Common Stock	X	7575	$0.314	Acquired	2709163	Direct
2022-04-18	Common Stock	X	189393	$0.079	Acquired	2898556	Direct
2022-04-18	Common Stock	X	28408	$0.079	Acquired	2926964	Direct
2022-04-18	Common Stock	X	7575	$0.314	Acquired	2934539	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-04-18	Options (right to purchase)	$0.314	X	7575	Disposed	2030-02-28	Common stock (7575)	Direct
2022-04-18	Options (right to purchase)	$0.314	X	7575	Disposed	2030-01-31	Common stock (7575)	Direct
2022-04-18	Options (right to purchase)	$0.079	X	189393	Disposed	2024-08-30	Common stock (189393)	Direct
2022-04-18	Options (right to purchase)	$0.079	X	28408	Disposed	2024-07-31	Common stock (28408)	Direct
2022-04-18	Options (right to purchase)	$0.314	X	7575	Disposed	2030-03-31	Common stock (7575)	Direct

Footnotes

F1: The Registrant issued the Reporting Person the options on August 30, 2019. The options vested on the date of grant and became exercisable upon completion of the Registrant's initial public offering.

F2: The Registrant issued the Reporting Person the options on July 31, 2019. The options vest as follows: (i) 9,469 options vested and became exercisable on July 31, 2020 and (ii) the balance of the options shall vest and become exercisable in 48 equal monthly installments such that the options shall vest in full by the 4th anniversary of the initial issuance date.